Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Brazilian electric utility, Companhia Energetica de Minas Gerais ( CIG - Analyst Report ) is slated to release its third quarter 2012 results on Wednesday, November 14. The current Zacks Consensus Estimate for earnings per share (EPS) is US$1.54 per ADR, roughly flat over the year-ago quarter.
Second Quarter Recap
Companhia Energetica de Minas Gerais reported quite an impressive second quarter 2012 financial results on August 14. Net income in the quarter was R$604.2 million (US$308.3 million), up 15% year over year. Earnings per ADR came in at US$0.42 per ADR.
Net revenue increased 16% to R$4,413.9 million (US$2,251.9 million), despite a 0.17% dip in electricity sold to 16,907 GWh at the end of the quarter.
For further details follow the link: Net Income Rises at CEMIG
Agreement/Magnitude of Estimate Revisions
In the last 30 days, an upward revision in one of the total three estimates pushed the Zacks Consensus Estimate up by 0.4% to US$2.57 per ADR for year 2012 while there was an increase in estimate for year 2013 by 11.5% to US$1.46 per ADR.
Our Take
Results in the third quarter 2012 are expected to improve on a sequential as well as on a year-over-year basis. Demand for electricity seems to be on the rise as Brazil prepares to host two major sporting events in the coming years. Also, the Government seems keen to invest heavily in infrastructure and power generation capabilities.
Cemig, the fifth largest electricity generator in Brazil, generates approximately 97% of electricity from hydroelectric sources. The company competes with Companhia Paranaense de Energia ( ELP - Analyst Report ) , which is expected to release its third quarter financial results on November 13. The Zacks Consensus Estimate for the quarter stands at US$0.48 per ADR.
Read the full reports :
Analyst Report on ELP
Analyst Report on CIG